Sign In
Buy ALLR
$1.58
-0.110 (-6.51%)
At Close: Jun 03, 2026
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
08:00am, Wednesday, 17'th Sep 2025
TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing s
Allarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track Designation
11:47am, Tuesday, 26'th Aug 2025
Allarity Therapeutics (NASDAQ:ALLR) shares more than doubled after the pharmaceutical firm annoucned that its investigational therapy for advanced ovarian cancer, stenoparib, has received Fast Track D
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
08:00am, Tuesday, 26'th Aug 2025
TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing steno
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
04:30pm, Friday, 15'th Aug 2025
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP ® companion diagnostic - S
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
08:00am, Tuesday, 15'th Jul 2025
TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopa
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
08:00am, Monday, 07'th Jul 2025
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopar
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
08:00am, Friday, 27'th Jun 2025
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopa
Allarity Therapeutics Announces Changes to Board of Directors
04:05pm, Wednesday, 11'th Jun 2025
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopa
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurcha
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
09:04am, Monday, 14'th Apr 2025
LOS ANGELES , April 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeut
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
09:09am, Tuesday, 25'th Mar 2025
LOS ANGELES , March 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeut
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity Therapeutics, Inc.") (NASDAQ:ALLR
Levi & Korsinsky Announces an Investigation on Behalf of Allarity Therapeutics, Inc. (ALLR) Shareholders Who May Have Been Affected by Fraud
04:00pm, Wednesday, 19'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity Therapeutics, Inc.") (NASDAQ:ALLR
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
03:52am, Wednesday, 19'th Mar 2025
LOS ANGELES , March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeut
